<DOC>
	<DOCNO>NCT03091933</DOCNO>
	<brief_summary>This study evaluate safety infuse anti-MiHA T cell line patient suffer hematologic malignancy relapse follow hematopoietic stem cell transplantation match donor .</brief_summary>
	<brief_title>Antiminor Histocompatibility Complex ( MiHA ) T Cells Patients With Relapsed Hematologic Malignancies Following Matched HSCT ( Guided Lymphocyte Immunopeptide Derived Expansion )</brief_title>
	<detailed_description>The GLIDE-201/44 trial primarily aim test safety anti-MiHA T cell line patient suffer hematologic malignancy relapse follow hematopoietic stem cell transplantation match donor . The anti-MiHA T cell line derive matched donor patient , original donor give patient . Both patient match donor undergo screen determine expression targetable MiHAs . Upon identification target MiHAs , donor cell collect apheresis prim select MiHA . In set , GLIDE 201/44 product cryopreserved , thaw administer single infusion target dose 4x10E+07 viable T cells/m2 ( range dose 0.4 4x10E+07 viable T cells/m2 ) . A second infusion offer patient observation period 42 day upon clinical evaluation treat physician . In absence secondary adverse event follow initial infusion , second infusion GLIDE 201/44 product could administer dose level 3-5 fold original dose .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<criteria>Prior allogeneic HLAmatched stem cell transplantation Any follow hematologic malignancy : Acute myeloid leukemia ( AML ) Acute lymphoblastic leukemia ( ALL ) Myelodysplastic syndrome ( MDS ) Presence HLA 2:01 / HLA 44:02 / HLAB*44:03 At least 6 month allogeneic hematopoietic stem cell transplantation Presence detectable malignant disease posttransplantation form molecular , cytogenetic hematologic relapse malignant disorder . Eligible receive cytoreductive chemotherapy Original stem cell donor available leukocyte donation . ECOG performance status â‰¤2 . Ability provide write consent . Accessible treatment follow . Presence targetable MiHA base exome sequence patient donor Active acute GVHD &gt; grade I Prior grade IIIIV acute GVHD within last year Uncontrolled chronic GVHD Prior administration donor lymphocyte infusion ( DLI ) Use Tcell deplete antibody previous 30 day Treatment immune suppressor ( oral parenteral steroid correspond dose prednisone great 7.5 mg/day , calcineurine inhibitor , rapamycin , mycophenolate mofetil , etc ) last 30 day . Uncontrolled active infection . Uncontrolled central nervous system involvement leukemia cell ( blast ) . AST ALT &gt; 2.5 x ULN ( CTCAE grade 2 ) Bilirubin &gt; 1.5 x ULN ( CTCAE grade 2 ) Creatinine clearance &lt; 50 mL/min Positive test human immunodeficiency virus ( HIV ) Positive pregnancy test ( woman childbearing age ) Lactating woman : safety therapy breast milk know . Estimated probability survive less 3 month Known allergy component GLIDE ( e.g. , dimethyl sulfoxide ) Intercurrent illness medical condition preclude safe administration plan protocol treatment require followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AML , ALL , MDS</keyword>
	<keyword>relapse hematopoietic malignancy</keyword>
	<keyword>Stem cell transplantation</keyword>
	<keyword>minor histocompatibilty antigen ( MiHA )</keyword>
</DOC>